Form 4: Altimmune Director Granted 48,800 Stock Options

Altimmune Director Diane Jorkasky was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Summary

• Diane Jorkasky, a Director of Altimmune, Inc. (ALT), was granted 48,800 stock options.
• The options have an exercise price of $3.92 per share.
• The transaction date for the option grant was September 25, 2025.
• The options will vest and become exercisable in substantially equal monthly installments over 12 months, starting from September 25, 2025, contingent on continued service.
• The expiration date for these stock options is September 25, 2035.
• Following this transaction, Diane Jorkasky beneficially owns 48,800 derivative securities directly.
• A Power of Attorney was executed on September 25, 2025, appointing Vipin K. Garg and Gregory Weaver to execute SEC filings on behalf of Diane Jorkasky.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a routine compensation event that aligns director interests with shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Risks

• The value of the stock options is contingent on Altimmune's common stock price exceeding the exercise price of $3.92 per share.
• The vesting schedule requires continued service, meaning the director must remain with the company for the options to fully vest.

Future Outlook

The stock options are subject to a 12-month vesting schedule, implying a future commitment of service from the director to fully realize the benefit of the grant.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, serving as a form of long-term incentive compensation to align leadership interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive and director compensation packages across publicly traded companies, particularly in growth-oriented sectors like biotech.
• The exercise price of $3.92, if at or above the market price on the grant date, is typical for incentive options.
• A 12-month vesting period is relatively short compared to some multi-year vesting schedules but is not uncommon for director grants, ensuring continued engagement.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aligns the director's incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The options will vest in monthly installments over the 12 months following September 25, 2025.
• Diane Jorkasky may exercise the vested options at any time before the expiration date of September 25, 2035, subject to company policy and insider trading rules.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. While it aligns the director's interests with shareholder value, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is a standard governance and compensation event.

Keywords

Altimmune, ALT, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Vesting